Total Payments
$78,042
2024 Payments
$53,912
Companies
34
Transactions
791
Medicare Patients
4,427
Medicare Billing
$1.3M
Payment Breakdown by Category
Research$52,075 (66.7%)
Other$13,266 (17.0%)
Food & Beverage$10,947 (14.0%)
Travel$1,234 (1.6%)
Education$520.14 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $52,075 | 2 | 66.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,266 | 8 | 17.0% |
| Food and Beverage | $10,947 | 770 | 14.0% |
| Travel and Lodging | $1,234 | 4 | 1.6% |
| Education | $520.14 | 7 | 0.7% |
Payments by Type
Research
$52,075
2 transactions
General
$25,967
789 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $52,075 | 2 | $0 (2024) |
| ABBVIE INC. | $9,337 | 162 | $0 (2024) |
| Allergan, Inc. | $8,919 | 103 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $1,149 | 91 | $0 (2024) |
| UCB, Inc. | $846.01 | 68 | $0 (2023) |
| EMD Serono, Inc. | $674.27 | 67 | $0 (2019) |
| Biohaven Pharmaceuticals, Inc. | $673.04 | 70 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $668.41 | 11 | $0 (2024) |
| Celgene Corporation | $622.42 | 76 | $0 (2024) |
| Lilly USA, LLC | $361.49 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,912 | 100 | Eli Lilly and Company ($52,075) |
| 2023 | $1,684 | 112 | AbbVie Inc. ($612.40) |
| 2022 | $4,077 | 122 | ABBVIE INC. ($2,933) |
| 2021 | $7,120 | 154 | AbbVie Inc. ($5,108) |
| 2020 | $8,687 | 101 | Allergan, Inc. ($7,795) |
| 2019 | $939.48 | 64 | Teva Pharmaceuticals USA, Inc. ($218.52) |
| 2018 | $1,067 | 86 | EMD Serono, Inc. ($350.29) |
| 2017 | $556.78 | 52 | EMD Serono, Inc. ($287.25) |
All Payment Transactions
791 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $28.83 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $7.52 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $4.32 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.25 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Eli Lilly and Company | — | — | In-kind items and services | $910.10 | Research |
| Study: EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY | ||||||
| 12/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.61 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $3.75 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $4.16 | General |
| Category: Neuroscience | ||||||
| 11/01/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.25 | General |
| Category: Neuroscience | ||||||
| 10/24/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $8.60 | General |
| Category: Neuroscience | ||||||
| 10/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $100.00 | General |
| Category: Rare Disease | ||||||
| 10/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.89 | General |
| Category: Neuroscience | ||||||
| 10/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.11 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.51 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: NEUROSCIENCE | ||||||
| 09/30/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.17 | General |
| Category: Neuroscience | ||||||
| 09/27/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY | Eli Lilly and Company | $52,075 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,058 | 36,460 | $1.2M | $281,966 |
| 2022 | 18 | 1,052 | 42,283 | $1.2M | $306,805 |
| 2021 | 22 | 1,228 | 51,073 | $1.5M | $393,933 |
| 2020 | 18 | 1,089 | 50,424 | $1.4M | $360,409 |
Total Patients
4,427
Total Services
180,240
Medicare Billing
$1.3M
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 45 | 35,124 | $456,612 | $171,692 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 196 | 196 | $145,236 | $23,644 | 16.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 176 | 301 | $136,052 | $21,958 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 165 | 211 | $117,105 | $17,782 | 15.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 73 | 73 | $71,759 | $9,273 | 12.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 107 | $40,874 | $6,597 | 16.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 17 | 48 | $37,584 | $5,493 | 14.6% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 12 | 41 | $34,240 | $4,678 | 13.7% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 22 | 76 | $27,360 | $4,139 | 15.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 39 | 40 | $29,720 | $3,909 | 13.2% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 21 | 22 | $25,784 | $3,569 | 13.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $21,824 | $3,289 | 15.1% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 37 | 37 | $23,088 | $2,986 | 12.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 27 | $8,397 | $1,294 | 15.4% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 37 | 41 | $2,460 | $1,238 | 50.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 68 | 72 | $432.00 | $423.36 | 98.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 56 | 40,938 | $532,194 | $195,056 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 185 | 185 | $122,797 | $22,889 | 18.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 147 | 254 | $114,808 | $19,859 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 169 | 227 | $112,081 | $19,796 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 104 | 127 | $43,402 | $7,598 | 17.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 49 | 51 | $50,133 | $6,868 | 13.7% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2022 | 14 | 45 | $37,890 | $5,640 | 14.9% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 29 | 81 | $29,160 | $4,692 | 16.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 44 | 44 | $32,692 | $4,514 | 13.8% |
About Dr. Cecile Becker, M.D
Dr. Cecile Becker, M.D is a Neurology healthcare provider based in Springfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750493540.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cecile Becker, M.D has received a total of $78,042 in payments from pharmaceutical and medical device companies, with $53,912 received in 2024. These payments were reported across 791 transactions from 34 companies. The most common payment nature is "" ($52,075).
As a Medicare-enrolled provider, Becker has provided services to 4,427 Medicare beneficiaries, totaling 180,240 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Springfield, IL
- Active Since 08/31/2006
- Last Updated 05/20/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1750493540
Products in Payments
- UBRELVY (Drug) $13,541
- QULIPTA (Drug) $3,245
- BOTOX (Biological) $1,091
- NURTEC ODT (Drug) $912.86
- Briviact (Drug) $743.88
- Rebif (Biological) $641.64
- ZEPOSIA (Drug) $631.80
- ACTHAR (Biological) $449.15
- AJOVY (Biological) $436.63
- ULTOMIRIS (Biological) $413.22
- EMGALITY (Drug) $361.49
- AUSTEDO (Drug) $310.02
- NUPLAZID (Drug) $306.41
- Aimovig (Biological) $260.40
- VYEPTI (Biological) $245.16
- BOTOX THERAPEUTIC (Biological) $242.24
- AJOVY (Drug) $168.48
- VYVGART (Drug) $122.83
- XYREM (Drug) $113.25
- INFINITY (Device) $112.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Springfield
David Clark, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Raymond Englander, Md, MD
Neurology — Payments: $167,481
Neurology $167,481
Dr. Jenifer Zhai, Md, MD
Neurology — Payments: $121,314
Neurology $121,314
Jennifer Lynch, Md, MD
Neurology — Payments: $73,454
Neurology $73,454
Jayant Acharya, Md, MD
Neurology — Payments: $56,046
Neurology $56,046
Rodger Elble, M.d, M.D
Neurology — Payments: $52,657
Neurology $52,657